RxDoctor Payments Data

Wyatt Thompson, PA

Medical · Lillington, NCNPI 1316188659

Payments from drug & device makers

$1,114in general payments, 2019–2025

Across 54 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$467
  • AbbVie$378
  • Lilly USA, LLC$77
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$56
  • AstraZeneca$48
  • Pfizer$21
  • plus $67 from 4 others

What the payments were for

  • Food & beverage$1,114100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,114 in reported general payments places this provider in the 65th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Medicare billing

Part B allowed, 2024
$22,554
Medicare patients
64
Services billed
477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide79$69,551
TrulicityDulaglutide46$46,160
RybelsusSemaglutide21$43,752
OzempicSemaglutide45$43,593
JanuviaSitagliptin Phosphate38$42,163
MounjaroTirzepatide34$37,673
FarxigaDapagliflozin Propanediol36$35,824
EliquisApixaban21$27,695
JardianceEmpagliflozin11$20,545
VraylarCariprazine Hcl11$15,659
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,200
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$13,194
Breo ElliptaFluticasone/Vilanterol25$13,060
Albuterol Sulfate HfaAlbuterol Sulfate170$4,676
Omega-3 Acid Ethyl Esters22$4,212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$467$87,34566 claims
AbbVieLinzess, Vraylar$378$85,20990 claims
Lilly USA, LLCTrulicity, Mounjaro$77$83,83480 claims
AstraZenecaFarxiga, Breztri Aerosphere$48$49,01756 claims
PfizerEliquis$21$27,69521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 878 medical providers in North Carolina.

Other medical in Lillington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →